SELECT found fewer major cardiovascular events with weekly semaglutide 2.4 mg in adults with established cardiovascular disease and overweight or obesity, without diabetes. This is evidence for a defined population and product—not a general heart-health claim for every GLP-1 offer.
A clinical result does not establish an individual insurance benefit.
The trial asked a heart-outcomes question
SELECT enrolled 17,604 adults aged 45 or older with established cardiovascular disease, BMI of at least 27 and no diabetes. Participants received weekly semaglutide 2.4 mg or placebo alongside standard care. The primary outcome combined cardiovascular death, nonfatal heart attack and nonfatal stroke. Mean follow-up was 39.8 months; Novo Nordisk funded the study.[1]
That question differs from asking which drug produces more weight loss. A weight-loss trial and a cardiovascular-outcomes trial can both be rigorous while measuring different benefits. Selecting a provider by the largest advertised weight-loss percentage can overlook the condition the prescriber is actually treating.
Our SURMOUNT-5 analysis addresses a direct weight-loss comparison. It should not be used to declare a cardiovascular winner. Start with the clinical goal, then identify the evidence matching that goal, and only then compare access and cost.
Put relative and absolute benefit side by side
The primary event occurred in 6.5% of the semaglutide group and 8.0% of the placebo group. The hazard ratio was 0.80, with a 95% confidence interval of 0.72–0.90. This is the source of the commonly reported 20% relative hazard reduction.[1]
| Measure | Result | What it means |
|---|---|---|
| Observed event proportions | 6.5% versus 8.0% | Participants with the composite outcome during follow-up |
| Difference in observed proportions | 1.5 percentage points | About 15 fewer per 1,000 participants, using rounded trial percentages |
| Relative hazard | Hazard ratio 0.80 | A time-to-event comparison; not a 20-point absolute reduction |
The absolute difference here is our subtraction of the rounded reported proportions. It is not a yearly rate, a lifetime estimate or a prediction for someone outside the trial population. The hazard ratio incorporates timing and should not be confused with that simple subtraction.
When evaluating a claim, ask for both descriptions. A large relative number can coexist with a smaller absolute difference when events are uncommon. That does not make the benefit unimportant; it makes the denominator essential to understanding its size.
Use the Wegovy coverage guide to distinguish clinical eligibility from a paid pharmacy claim.
A meaningful benefit still has treatment burdens
Adverse events led to permanent treatment discontinuation in 16.6% of the semaglutide group and 8.2% of the placebo group.[1] This is a different outcome from cardiovascular events, with a different meaning. Do not subtract discontinuations from events prevented to manufacture a net-benefit score.
A useful clinical discussion asks whether the expected benefit fits the person’s condition, preferences and ability to tolerate treatment. A useful purchasing discussion asks how follow-up is organized when treatment is difficult. Those conversations connect, but the seller’s refund policy cannot settle a clinical benefit-risk decision.
Ask how questions reach the prescriber, how an appointment is arranged and what happens financially if the treatment changes. A service that advertises ongoing support should explain its scope. Messaging access alone does not establish response time, specialist coordination or the ability to manage every symptom remotely.
The approved indication is product-specific
FDA approved Wegovy injection to reduce cardiovascular death, heart attack and stroke risk in adults with cardiovascular disease and overweight or obesity, alongside reduced-calorie diet and increased physical activity.[2] That regulatory decision is not an approval of every product sold under the ingredient name semaglutide.
SELECT does not establish that a particular compounded preparation delivers the same cardiovascular outcome, nor that a person without established cardiovascular disease will obtain the same benefit. It also does not compare semaglutide against tirzepatide. Avoid turning an absence of a head-to-head comparison in this study into evidence of superiority over another medicine.
If heart-risk reduction is part of the treatment goal, ask the clinician to identify the exact product and indication. Our product evidence guide explains why formulation and approval status belong in the comparison before price. The generic ingredient label is too broad to complete that task.
Translate the evidence into an access question
A relevant clinical indication can change the coverage conversation, but it does not guarantee that a particular insurance claim will be approved. Ask the plan and prescriber which benefit route and documentation apply. The Medicare coverage analysis separates ordinary Part D coverage from the temporary Bridge pathway; the correct route depends on the actual situation.
Our Ro review examines a branded-access service with a separate care fee. Compare that fee with the work your existing clinician can provide before buying another membership. A pharmacy benefit and a private care subscription remain separate purchases even when the service helps with paperwork.
Use the quote checklist to collect the exact medication payment, care fee and renewal terms, then compare suitable care models in the provider shortlist. SELECT supplies evidence about an outcome. It does not tell you which website to buy through, what your insurer will pay or how much additional care is worth to you.